Comparative Pharmacology
Head-to-head clinical analysis: ISIBLOOM versus NORTREL 1 35 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISIBLOOM versus NORTREL 1 35 21.
ISIBLOOM vs NORTREL 1/35-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ISIBLOOM is a selective serotonin reuptake inhibitor (SSRI) that increases serotonergic neurotransmission by blocking the reuptake of serotonin at the presynaptic neuron, thereby enhancing serotonin levels in the synaptic cleft.
Combination of ethinyl estradiol (estrogen) and norethindrone (progestin) suppresses gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation, altering cervical mucus to impede sperm penetration, and inducing endometrial changes that reduce implantation likelihood.
Adults: 200 mg orally once daily; increase to 400 mg once daily after 2 weeks if tolerated. Maximum dose: 600 mg once daily.
One tablet orally once daily for 21 days, followed by 7 days off, then repeat.
None Documented
None Documented
Terminal elimination half-life is 12 hours (range 10–14 hours) in healthy adults, permitting twice-daily dosing; prolonged to 24–30 hours in severe renal impairment (CrCl <30 mL/min).
Norethindrone: 5-14 hours; Ethinyl estradiol: 17-24 hours. Steady-state achieved after 10 days.
Renal excretion of unchanged drug accounts for approximately 60% of elimination; biliary/fecal excretion accounts for 35%; minor metabolism (<5%) via CYP3A4.
Renal 50-60% as metabolites, fecal 40-50% as conjugates, <1% unchanged
Category C
Category C
Oral Contraceptive
Oral Contraceptive